Ocean Biomedical Faces Delisting Notice

Ticker: OCEA · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1869974

Sentiment: bearish

Topics: delisting, listing-rules, regulatory

Related Tickers: OCEA

TL;DR

OCEAN BIOMEDICAL GOT A DELISTING WARNING - STOCK MAY BE DELISTED SOON.

AI Summary

Ocean Biomedical, Inc. filed an 8-K on October 22, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of October 16, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31st. This filing also includes financial statements and exhibits.

Why It Matters

This filing indicates potential delisting from an exchange, which could significantly impact the stock's liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain traded on a public exchange, posing a significant risk to investors.

Key Players & Entities

FAQ

What specific listing rule or standard has Ocean Biomedical, Inc. failed to satisfy?

The filing states "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard" but does not specify which particular rule or standard has been violated.

What is the earliest date for which an event is reported in this 8-K filing?

The earliest event reported is dated October 16, 2024.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted on October 22, 2024.

What is the primary business of Ocean Biomedical, Inc. according to its SIC code?

Ocean Biomedical, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).

Has Ocean Biomedical, Inc. undergone any previous name changes?

Yes, the company was formerly known as Aesther Healthcare Acquisition Corp. until a name change on February 14, 2023, and prior to that, it was Ocean Biomedical, Inc./DE.

Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-22 16:45:13

Key Financial Figures

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2024 OCEAN BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-40793 87-1309280 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 55 Claverick St. , Room 325 Providence , RI 02903 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (401) 444-7375 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value OCEA The Nasdaq Stock Market LLC Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50 OCEAW The Nasdaq Stock Market LLC (Title of Each Class) (Trading Symbol) (Name of Each Exchange on Which Registered) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (CFR 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Ocean Biomedical, Inc. ( NASDAQ : OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) (the "Rule") because it had not filed its Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the "Forms 10-Q"), respectively. Based on its review and the materials submitted on June 17, 2024 and August 27, 2024, Staff granted the Company an exception until October 14, 2024, to regain compliance with the Rule. Upon further review, Staff determined that the Company did not meet the terms of the exception. Specifically, the Company has not filed the either its Form 10-K or Forms 10-Q as required by the Rule. The Company will appeal Staff's determination to a Hearings Panel (the "Panel"), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated October 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2024 OCEAN BIOMEDICAL, INC. By: /s/ Jolie Kahn Jolie Kahn Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing